Form 4: Summit Therapeutics Co-CEO Mahkam Zanganeh Reports Share Transactions and Beneficial Ownership

Summit Therapeutics Co-Chief Executive Officer, Mahkam Zanganeh, filed a Form 4 detailing share transactions and beneficial ownership, including shares held directly, indirectly through trusts, and by her spouse.

Summary

• Mahkam Zanganeh, Co-Chief Executive Officer of Summit Therapeutics, filed a Form 4 disclosing changes in her beneficial ownership of the company's stock.
• The filing includes transactions made on January 2, 2025, and details shares held directly, indirectly through trusts, and by her spouse.
• Ms. Zanganeh disclaims beneficial ownership of shares held by trusts and her spouse, except to the extent of her pecuniary interest.
• The report indicates that Ms. Zanganeh's spouse was granted stock options on January 2, 2025, and January 2, 2024.
• The filing also notes that Ms. Zanganeh acquired beneficial ownership of securities held by her spouse upon their marriage on December 18, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, and does not contain any information that would be considered positive or negative from an investment perspective. It is a neutral disclosure of transactions.

Management Comments

• The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Industry Context

Form 4 filings are standard practice for company insiders to report changes in their beneficial ownership of company stock, ensuring transparency and compliance with SEC regulations.

Comparison to Industry Standards

• Form 4 filings are a common practice for publicly traded companies, and the information provided is consistent with what is typically disclosed in such filings.
• The level of detail provided, including the number of shares, option prices, and vesting schedules, is standard for these types of reports.
• The reporting of indirect ownership through trusts and family members is also a common practice.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the ownership of company stock by a key executive.
• The information is relevant to investors who track insider transactions as part of their investment analysis.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Options, Warrants, Share Transactions, Summit Therapeutics, SMMT, Mahkam Zanganeh, Co-CEO